By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Humans have been shaping life for thousands of years through farming, breeding, and selective cultivation. But with modern tools like CRISPR, we can now directly edit DNA itself—rewriting the very ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.

Scientists at Gladstone Institutes and UC San Francisco (UCSF) have mapped the intricate network of genetic switches that ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Clustered regularly interspaced palindromic repeats(CRISPR) gene editing, known for its precision, is revolutionizing tumor research and treatment. This article covers the evolution of the CRISPR ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.